Osilodrostat

Chemical formula: C₁₃H₁₀FN₃  Molecular mass: 227.242 g/mol  PubChem compound: 44139752

Active ingredient description

Osilodrostat is a cortisol synthesis inhibitor. It potently inhibits 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In Cushing’s disease, the fall in plasma cortisol concentration also stimulates ACTH secretion, via the feedback mechanism which accelerates steroid biosynthesis.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
H02CA02 H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02C Antiadrenal preparations → H02CA Anticorticosteroids
Discover more medicines within H02CA02

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
ISTURISA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ISTURISA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 928134-65-0
DrugBank Drug: DB11837
PubChem Compound: 44139752
RxNorm Ingredient: 2286252
SNOMED-CT Concept: 863916001
Osilodrostat (substance)
UNII Identifier: 5YL4IQ1078
OSILODROSTAT

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.